Desitin is focused on pharmaceuticals for the treatment of epilepsy. It is the only manufacturer that offers the entire spectrum of products recommended by the WHO for the treatment of epilepsy.
Desitin not only offers a wide range of different therapeutics, but also a broad spectrum of presentations and dosage strengths.
Whereas most of these preparations have been developed inhouse by Desitin and successfully sold within various countries of Europe, co-operations with licensors and the successful marketing of products licenced represent a corner stone of Desitin’s latest developments.
Among the five products which are presently in the centre of our marketing efforts four products, namely Xeomin®, Teglutik®, Apomorphin Archimedes®, Diacomit® and Ameluz®, are licenced from European partner companies (Merz, Italfarmaco, Kyowa Kirin, Biocodex, Biofrontera).